This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Macrophages present a central line of defense against cancer by preventing inflammation and eliminating tumor cells. However, tumor-associated-macrophages (TAMs) at times protect the tumor from immune responses and facilitate its growth. Elevated levels of TAMs are commonly associated with poor outcomes, and depleting them can prevent cancer progression and metastasis. However, the signals mediating these opposing macrophage identities are unknown. Dr. Duttke aims to figure out what makes TAMs different from normal, anti-cancer macrophages by analyzing macrophages/TAMs in tumors and healthy patient tissues. Understanding the pathways linked to TAM identity may single out targets for therapies aiming to suppress TAMs and aid tumor elimination.
University of California, San Diego | All Cancers, Lung Cancer | 2015 | Christopher K. Glass, M.D., Ph.D.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
A recent diabetes-related discovery by CRI Lloyd J. Old STAR Dr. Andrea Schietinger has promising implications for cancer immunotherapy
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.